Scholarlink

Background <p>Loss of skeletal muscle mass and function in aging individuals is closely linked to physical deterioration and disability. Because exosomes of human umbilical cord-derived mesenchymal stromal cells (hucMSC-Exos) have been widely used to treat various human diseases, we examined their effects on aging-associated muscle atrophy and dysfunction in senescence-accelerated mouse prone 10 (SAMP10) mice, an animal model of human Sarcopenia. </p> Methods <p>Twenty-four-week-old male SAMP10 mice were randomly assigned to a non-treatment or hucMSC-Exos treatment group.</p> Results <p>Twelve weeks after intravenous injection of hucMSC-Exos, the treatment group mice showed improvements in skeletal muscle morphology and performance, and elevated levels of the proteins phospho-mammalian target of rapamycin (p-mTOR), myosin heavy chain (MHC), peroxisome proliferator-activated receptor-γ co-activator, and sirtuin1 (Sirt1) in gastrocnemius muscle tissues. HucMSC-Exos also improved muscle mitochondrial biogenesis and lipid drop accumulation in the gastrocnemius muscles. In in vitro experiments, hucMSC-Exos improved cell viability, senescence, apoptosis, and differentiation in association with induction of molecules related to anti-apoptosis (Bcl-2), differentiation (myogenin, MyoD1, myogenic factor-5, and myogenic factor-6), and protein anabolism (p-mTOR, MHC, Sirt1, phospho-AMP-activated protein kinase, phosphor-extracellular signal-regulated kinase1/2, and glycogen synthase kinase3alpha/beta) in C2C12 cells under our experimental conditions.</p> Conclusions <p>Our findings indicate that hucMSC-Exos treatment ameliorated skeletal muscle atrophy and dysfunction via mitochondrial biogenesis, anti-apoptosis, and protein anabolism mechanisms that might be dependent on an mTOR and Sirt1/PGC1α signaling pathways, indicating that hucMSC-Exos may have promise as a treatment for the management of aging-related frailty and sarcopenia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Human umbilical cord-derived mesenchymal stromal cell exosomes ameliorate aging-associated skeletal muscle atrophy and dysfunction in SAMP10 mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月28日

查看全文
  • Zhe Huang,
  • Limei Piao,
  • Xiangkun Meng,
  • Aiko Inoue,
  • Kazuhiro Hitomi,
  • Hiroyuki Umegaki,
  • Masafumi Kuzuya,
  • Xian Wu Cheng

摘要

Background

Loss of skeletal muscle mass and function in aging individuals is closely linked to physical deterioration and disability. Because exosomes of human umbilical cord-derived mesenchymal stromal cells (hucMSC-Exos) have been widely used to treat various human diseases, we examined their effects on aging-associated muscle atrophy and dysfunction in senescence-accelerated mouse prone 10 (SAMP10) mice, an animal model of human Sarcopenia.

Methods

Twenty-four-week-old male SAMP10 mice were randomly assigned to a non-treatment or hucMSC-Exos treatment group.

Results

Twelve weeks after intravenous injection of hucMSC-Exos, the treatment group mice showed improvements in skeletal muscle morphology and performance, and elevated levels of the proteins phospho-mammalian target of rapamycin (p-mTOR), myosin heavy chain (MHC), peroxisome proliferator-activated receptor-γ co-activator, and sirtuin1 (Sirt1) in gastrocnemius muscle tissues. HucMSC-Exos also improved muscle mitochondrial biogenesis and lipid drop accumulation in the gastrocnemius muscles. In in vitro experiments, hucMSC-Exos improved cell viability, senescence, apoptosis, and differentiation in association with induction of molecules related to anti-apoptosis (Bcl-2), differentiation (myogenin, MyoD1, myogenic factor-5, and myogenic factor-6), and protein anabolism (p-mTOR, MHC, Sirt1, phospho-AMP-activated protein kinase, phosphor-extracellular signal-regulated kinase1/2, and glycogen synthase kinase3alpha/beta) in C2C12 cells under our experimental conditions.

Conclusions

Our findings indicate that hucMSC-Exos treatment ameliorated skeletal muscle atrophy and dysfunction via mitochondrial biogenesis, anti-apoptosis, and protein anabolism mechanisms that might be dependent on an mTOR and Sirt1/PGC1α signaling pathways, indicating that hucMSC-Exos may have promise as a treatment for the management of aging-related frailty and sarcopenia.